Wednesday, May 25, 2022
Sheila Bangalore
The Wharton Club of Southern California invites all members and non-members to this continuing series. Catalysts represent leaders across different industries that continually drive change to enhance their business and community. Wharton Women proudly sponsors this new virtual series designed to create and foster collisions through rich discussion.
When: Wed, May 25, 5:30-6:30pm PDT
Where: Online event (Zoom link will be sent to registered participants in advance of the event)
Cost: Paid Members, Free; Non-Members, $10
The Catalyst:
Barbara Troupin M95 WG95
Barbara Troupin is a business-centric Biotech/Pharma/Life Science Executive and Board Advisor who scales for growth through clinical development, global regulatory strategy and medical/commercial positioning to maximize the probability of success. She is known for deep therapeutic area expertise with delivery of scientific and operational excellence, while fostering impactful relationships with all stakeholders. She maintains a comprehensive understanding of drug development and regulatory landscape from IND to NDA defense in the US and EU, resulting in multiple product approvals and US launch. As an insightful member of the senior leadership team with extensive board interaction, Barbara is ready to guide a company in scaling for growth while asking the right questions for critical decisions. Notable achievements:
• FDA APPROVALS: Obtained 20-2 vote as Lead Clinical Presenter at Qsymia FDA Advisory Committee, leading to FDA approval for VIVUS. Supported NDA filings for Stendra and Evamist, both resulting in approvals.
• DEVELOPMENT STRATEGY: Builds comprehensive development programs addressing medical and scientific questions, regulatory requirements and strategic compound positioning to maximize value. Drives early Go-No Go decisions, halting studies/development when not supportive of compound success, and develops IP to protect innovation (holds two patents).
• REGULATORY STRATEGY TRANSFORMATION: Revised Clinical Development Plans to achieve required regulatory elements addressing both safety and efficacy for successful FDA filing/approval – getting written FDA agreement and increasing regulatory probability of global clinical/regulatory success.
• MEDICAL LEADERSHIP: Built medical affairs functionality from start to launch; evolving medical landscapes, building expert relationships, interacting at the highest level of scientific and medical rigor.
• BOARD SERVICE: Participated in Board meetings and joint Board/Management Scientific & Technical Strategy Committee for Aquinox (Nasdaq: AQXP), obtaining board buy-in for regulatory strategy overhaul. Presented to/participated in discussions with Boards of Aquinox, Apricus, and VIVUS (Nasdaq:VVUS).
Barbara holds an MD in Medicine from Perelman School of Medicine at The University of Pennsylvania and an MBA in Healthcare Management from The Wharton School.
The Host:
Sheila Bangalore WG21
As a chief legal and strategy officer, Sheila Bangalore honed her legal/compliance, corporate strategy and governance experience over 20 years in senior roles across multinational, highly regulated, technology (B2B/C) and retail businesses, including Zappos, Bally Technologies, Aristocrat Gaming and MP Materials. Sheila’s results-oriented focus, collaborative style and ability to develop and lead high-performing, diverse teams enable growth and transformation. Sheila received her MBA in Finance from The Wharton School at the University of Pennsylvania, her JD from the Washington University School of Law in St. Louis, and her BA from Tufts University.
